SCHEMBL232161

SCHEMBL232161

COC(=O)c1cc(Oc2ccc(F)c(F)c2)cc(C(=O)c2ccc(N(C)c3ccc(Cl)cc3)cc2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.42
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
LTC4S Q16873 5/20 0.40
LMNA P02545 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
USP2 O75604 1/20 0.39
ELANE P08246 1/20 0.38
TUBB4A P04350 1/20 0.38
TUBB P07437 1/20 0.38
TUBA3C P0DPH7 1/20 0.38
TUBA1B P68363 1/20 0.38
TUBA4A P68366 1/20 0.38
TUBB4B P68371 1/20 0.38
TUBB3 Q13509 1/20 0.38
TUBB2A Q13885 1/20 0.38
TUBB8 Q3ZCM7 1/20 0.38
TUBA3E Q6PEY2 1/20 0.38
TUBA1A Q71U36 1/20 0.38
TUBA1C Q9BQE3 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL230420 0.89 LTC4S (0.43) HPGDMAPTSMN1; SMN2LTC4SLMNA
SCHEMBL231253 0.86 LMNA (0.46) HPGDMAPTSMN1; SMN2LTC4SLMNA
SCHEMBL232400 0.83 HPGD (0.46) HPGDMAPTSMN1; SMN2LTC4SLMNA
SCHEMBL232867 0.82 MAPT (0.42) HPGDMAPTSMN1; SMN2LTC4SLMNA
SCHEMBL27850790 0.81 L3MBTL1 (0.50) HPGDMAPTSMN1; SMN2LTC4SLMNA
SCHEMBL1724841 0.81 LTC4S (0.38) HPGDMAPTSMN1; SMN2LTC4SLMNA
SCHEMBL2743161 0.79 LMNA (0.48) HPGDMAPTSMN1; SMN2LTC4SLMNA
SCHEMBL229900 0.79 TUBB4A (0.45) HPGDMAPTSMN1; SMN2LTC4SLMNA
SCHEMBL230032 0.79 MAPT (0.44) HPGDMAPTSMN1; SMN2LTC4SLMNA
SCHEMBL232232 0.78 LMNA (0.50) HPGDMAPTSMN1; SMN2LTC4SLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406220-A1 BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS Biolipox AB (SE) 2012-01-18 EP disclosed
US-20120004228-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors BIOLIPOX AB (SW) 2012-01-05 US disclosed
WO-2010103279-A1 BIS AROMATIC COMPOUNDS FOR USE AS LCT4 SYNTHASE INHIBITORS BIOLIPOX AB (SE) 2010-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004228-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors LTC4S, LTB4R2, LTB4R HPGD 169/4885MAPT 4117/4885SMN1; SMN2 4788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.